Supplementary Figure 6 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• Prognostic stratification reveals insights into patient outcomes in metastatic urothelial cancer.
• ctDNA and tissue assessments demonstrate a strong correlation with ECOG performance status, aiding treatment decisions.
• Assessment involves ctDNA analysis alongside tissue examination of ERBB2 and HER2 alterations.
• Highlights the need for personalized treatment approaches based on biomarker evaluations in metastatic urothelial cancer.